logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin : Favorable subsets of patients with unknown-primary carcinoma ?

    Article - En anglais

    Purpose 

    The objectives of this study were to assess clinica outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA).

    Patients and Methods 

    The 1,400 patients analyzed were referred to our unknown-primary tumor (UPT) clinic from January 1,1987 through July 31,1994.

    Clinical data from these patients were entered into a computerized data base for storage, retrieval, and analysis.

    Survival was measured from the time of diagnosis ; survival distribution was estimated using the product-limit method.

    Multivariate survival analyses were performed using proportional hazards regression and by recursive partitioning.

    Results 

    Nine hundred seventy-seven patients were diagnosed with unknown-primary carcinoma (UPC) and 337 of these patients had PDC or PDA.

    No clinical differences were identified among patients with PDC, PDA, or UPC patients with other carcinoma or adenocarcinoma subtypes.

    PDC patients enjoyed better survival than PDA patients.

    Poor cellular differentiation was not an important prognostic variable.

    Variables predictive of survival included lymph node metastases, sex, number of metastatic sites, histology (PDC v PDA), and age.

    Although chemotherapy did not appear to influence survival for the entire group of PDC or PDA patients, a subset of patients with good prognostic features experienced median survival durations of up to 40 months. (...)

    Mots-clés Pascal : Carcinome, Adénocarcinome, Origine inconnue, Histopathologie, Différenciation, Cytodifférenciation, Pronostic, Evolution, Survie, Homme, Epidémiologie, Tumeur maligne, Anatomopathologie

    Mots-clés Pascal anglais : Carcinoma, Adenocarcinoma, Undetermined primary site, Histopathology, Differentiation, Cell differentiation, Prognosis, Evolution, Survival, Human, Epidemiology, Malignant tumor, Pathology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0302577

    Code Inist : 002B04C. Création : 15/07/1997.